Eli Lilly and Company CEO Net Worth

Last Updated Mar 10, 2025
CEO NameDavid A. Ricks
NationalityUnited States
Net Worth Estimation$100 million

David A. Ricks, current CEO of Eli Lilly and Company, has an estimated net worth of around $100 million due to his high executive compensation, substantial stock awards, and long-term equity growth from his tenure at the global pharmaceutical leader. His wealth primarily stems from Lilly stock appreciation, performance incentives, and accumulated bonuses awarded over years of service.

David A. Ricks, CEO of Eli Lilly and Company, has an estimated net worth of $100,000,000, which is 11.1% higher than the industry's maximum estimated CEO net worth of $90,000,000. His net worth also exceeds the industry minimum by 900%.

Business Category: Healthcare

Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 90000000 USD


David A. Ricks Performance in Eli Lilly and Company

David A. Ricks, CEO of Eli Lilly and Company, demonstrates strategic leadership by driving innovation and accelerating drug development pipelines. His decisive actions emphasize operational efficiency and expansion into emerging markets, enhancing the company's global footprint. Under Ricks' tenure, Eli Lilly has seen improved financial performance and strengthened R&D capabilities, significantly boosting shareholder value and industry reputation.


Latest News

Eli Lilly and Company: Latest News and CEO Insights

Eli Lilly recently completed acquiring Verve Therapeutics and is advancing its cardiovascular genetic medicine pipeline, alongside ongoing discussions about obesity drug pricing with the U.S. government. CEO David Ricks emphasizes potential cooperation with the Trump administration on obesity issues despite policy differences.
Source: http://www.lilly.com/news/press-releases



Disclaimer.
The information provided in this document is for general informational purposes only and is not guaranteed to be complete. While we strive to ensure the accuracy of the content, we cannot guarantee that the details mentioned are up-to-date or applicable to all scenarios. Topics about Eli Lilly and Company are subject to change from time to time.

Comments

No comment yet